ICT 107

Drug Profile

ICT 107

Alternative Names: Cancer vaccine - ImmunoCellular Therapeutics; Dendritic cell vaccines - ImmunoCellular Therapeutics; ICT-107

Latest Information Update: 05 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No
  • Available For Licensing Yes - Glioblastoma

Highest Development Phases

  • Suspended Glioblastoma

Most Recent Events

  • 21 Jun 2017 ICT 107 is available for licensing as of 21 Jun 2017. www.imuc.com
  • 21 Jun 2017 Suspended upon strategic review of financing and development strategies for ICT 107 - Phase-III for Glioblastoma (Combination therapy, First-line therapy) in Canada, USA, Austria, Germany, Netherlands and Spain (Intradermal)
  • 25 Jul 2016 ImmunoCellular Therapeutics receives regulatory approvals for a phase III trial in Glioblastoma Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top